12:00 AM
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Neutrolin regulatory update

CorMedix said it received CE Mark approval for its Neutrolin catheter lock solution as a Class III device to prevent catheter-related bloodstream infection and maintain catheter patency in patients with central venous...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >